|
| PPARs激动剂与骨质疏松症 |
| PPARs agonists and osteoporosis |
| |
| DOI：10.3969/j.issn.1006-7108.2015.06.029 |
| 中文关键词: PPARs激动剂、骨质疏松症、糖尿病 |
| 英文关键词:PPARs agonists Osteoporosis Diabetes |
| 基金项目:哈尔滨医科大学大学生创新项目（2014157022） |
|
| 摘要点击次数: 1224 |
| 全文下载次数: 1173 |
| 中文摘要: |
| 过氧化物酶增殖激活受体(Peroxisome proliferator activated receptors,PPARs)是核激素受体家族中的配体激活受体，包括3种亚型：PPARα、PPARβ/δ和PPARγ，具有增强机体对胰岛素敏感性，调节体内糖平衡以及脂肪的分化、生成等多种生物学功能。PPARγ激动剂作为胰岛素增敏剂治疗2型糖尿病的重要药物，可引起糖尿病性骨质疏松症(Diabetic Osteoporosis，DO)，DO发病机制复杂，致残、致死率高。本文主要对PPARs激动剂在治疗糖尿病中对骨的影响进行综述。 |
| 英文摘要: |
| Peroxisome proliferator activated receptors (PPARs) are ligand-stimulating receptors in nuclear receptor family, including 3 subtypes, PPAR?, PPAR?/?, and PPAR?. Their functions include the improvement of the insulin sensibility of the body, regulation of glucose balance and lipid differentiation and formation, and other biological activities. PPAR? stimulant as an important drug for improving insulin sensibility in type II diabetes treatment, can cause diabetic osteoporosis (DO). The pathogenesis of DO is complicated. The morbidity and mortality of DO are high. This paper reviews the effect of PPARs stimulants on bone in the treatment of diabetes. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |